Biochemistry And Microbial Sciences - Research Publications
Permanent URI for this collectionhttps://kr.cup.edu.in/handle/32116/27
Browse
2 results
Search Results
Item Long non-coding RNAs as critical regulators and novel targets in cervical cancer: current status and future perspectives(Springer, 2023-04-25T00:00:00) Ranga, Shalu; Yadav, Ritu; Chhabra, Ravindresh; Chauhan, Meenakshi B.; Tanwar, Mukesh; Yadav, Chetna; Kadian, Lokesh; Ahuja, ParulCervical cancer is among the leading causes of cancer-associated mortality in women. In spite of vaccine availability, improved screening procedures, and chemoradiation therapy, cervical cancer remains the most commonly diagnosed cancer in 23 countries and the leading cause of cancer deaths in 36 countries. There is, therefore, a need to come up with novel diagnostic and therapeutic targets. Long non-coding RNAs (lncRNAs) play a remarkable role in genome regulation and contribute significantly to several developmental and disease pathways. The deregulation of lncRNAs is often observed in cancer patients, where they are shown to affect multiple cellular processes, including cell cycle, apoptosis, angiogenesis, and invasion. Many lncRNAs are found to be involved in the pathogenesis as well as progression of cervical cancer and have shown potency to track metastatic events. This review provides an overview of lncRNA mediated regulation of cervical carcinogenesis and highlights their potential as diagnostic and prognostic biomarkers as well as therapeutic targets for cervical cancer. In addition, it also discusses the challenges associated with the clinical implication of lncRNAs in cervical cancer. � 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.Item Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise(Baishideng Publishing Group Inc, 2023-01-15T00:00:00) Singh, Amit Kumar; Singh, Shiv Vardan; Kumar, Ramesh; Kumar, Shashank; Senapati, Sabyasachi; Pandey, Abhay KLiver cancer is a severe concern for public health officials since the clinical cases are increasing each year, with an estimated 5-year survival rate of 30%�35% after diagnosis. Hepatocellular carcinoma (HCC) constitutes a significant subtype of liver cancer (approximate75%) and is considered primary liver cancer. Treatment for liver cancer mainly depends on the stage of its progression, where surgery including, hepatectomy and liver transplantation, and ablation and radiotherapy are the prime choice. For advanced liver cancer, various drugs and immunotherapy are used as first-line treatment, whereas second-line treatment includes chemotherapeutic drugs from natural and synthetic origins. Sorafenib and lenvatinib are first-line therapies, while regorafenib and ramucirumab are secondline therapy. Various metabolic and signaling pathways such as Notch, JAK/ STAT, Hippo, TGF-?, and Wnt have played a critical role during HCC progression. Dysbiosis has also been implicated in liver cancer. Drug-induced toxicity is a key obstacle in the treatment of liver cancer, necessitating the development of effective and safe medications, with natural compounds such as resveratrol, curcumin, diallyl sulfide, and others emerging as promising anticancer agents. This review highlights the current status of liver cancer research, signaling pathways, therapeutic targets, current treatment strategies and the chemopreventive role of various natural products in managing liver cancer � The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved